AstraZeneca Divests US Rights of Synagis & MEDI8897 to Sobi for Prevention of Serious Lower Respiratory Tract infection (LRTI)

 AstraZeneca Divests US Rights of Synagis & MEDI8897 to Sobi for Prevention of Serious Lower Respiratory Tract infection (LRTI)

AstraZeneca Divests US Rights of Synagis & MEDI8897 to Sobi for Prevention of Serious Lower Respiratory Tract infection (LRTI)

 Shots:

  • AstraZeneca to get $1.5B upfront ($1B in cash & 0.5B equity) plus $470M sales based milestones for Synagis. AZ has also sold US rights for its new candidate MEDI8897 to Sobi, for $175M milestone for BLA submission plus $110M development milestones & $60M non-contingent payment during 2019-2021
  • Sobi to get hold of the US rights for Synagis and MEDI8897 plus additional 8% equity in AZ (with terms & condition of not selling it before 12 mos. on closing of transaction). The profit and loss will be shared for AZ will continue to develop Synagis in collaboration with Sanofi Pasteur (division of Sanofi)
  • Synagis (palivizumab) is a novel mAb, inhibiting RSV F protein approved for RSV disease. MEDI8897 is a mAb, anti-RSV F indicated for prevention of LRTI caused by RSV

Click here to read full press release/ article | Ref: AstraZeneca| Image: Dennis Partners

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post